🔒 Secure Checkout
|
Free Research Guides →
Clinical Body Composition Research

The Next Generation of Metabolic Optimisation.

A research guide to the peptides studied for precision appetite control and cellular energy utilization.

View Compounds

Precision Metabolic Targeting

The science of incretin mimetics — modern compounds that target GLP-1, GIP, and Glucagon receptors for multi-pathway metabolic research.

01

Appetite Control

Silences the “hunger noise” and signals the brain to feel full faster and for longer durations.
Explore →
02

Metabolic Shift

Encourages the body to prioritize stored adipose tissue as a primary fuel source during research protocols.
Explore →
03

Thermic Support

Optimizes resting metabolic rate to support sustainable, measurable weight management outcomes.
Explore →

The Three Compounds

How the leading metabolic research compounds differ — with links to each full guide.

01
Retatrutide
Triple GIP, GLP-1 and glucagon receptor agonist. Phase 2: 24.2% mean weight loss at 48 weeks at the highest dose. Phase 3 TRIUMPH-1 (May 2026): up to 25.0% at 80 weeks. Investigational — not yet approved.1
Guide →
02
Tirzepatide
Dual GIP and GLP-1 receptor agonist. SURMOUNT-1: up to 20.9% mean weight loss at 72 weeks; SURMOUNT-5: 20.2% versus 13.7% for semaglutide. Approved as Mounjaro and Zepbound.2,3
Guide →
03
Cagrilintide
Long-acting amylin analogue acting on satiety pathways separate from the incretin system. Combined with semaglutide (CagriSema): 20.4% mean weight loss at 68 weeks; under FDA review with a decision expected in late 2026.4,5
Guide →

What’s New in 2026

The developments reshaping metabolic research this year.

APR
Oral GLP-1 approved
Orforglipron (Foundayo), a once-daily small-molecule GLP-1 agonist with no food or water restrictions, was approved by the FDA.
MAY
Retatrutide phase 3
TRIUMPH-1 reported up to 25.0% mean weight loss at 80 weeks, with dysaesthesia emerging as a new safety signal alongside gastrointestinal effects.
Guide →
2026
CagriSema vs tirzepatide
In the head-to-head REDEFINE 4 trial, CagriSema produced 23.0% weight loss versus 25.5% with tirzepatide and missed its non-inferiority endpoint.
Guide →
AUG
Cardiovascular indication
The FDA approved tirzepatide to reduce major cardiovascular events in type 2 diabetes, based on SURPASS-CVOT.
Guide →

Evidence Quality & Limitations

Weight-loss figures come from different trials with different populations, durations and analysis methods, so they are not directly comparable — only head-to-head trials such as SURMOUNT-5 and REDEFINE 4 support direct comparisons. Across all three compounds, gastrointestinal effects are the most common adverse events, part of the weight lost is lean mass, and weight is largely regained when treatment stops. Descriptions elsewhere on this page, such as “Thermic Support”, summarise mechanisms rather than measured outcomes.

  1. Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389:514–26. PubMed
  2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205–16. PubMed
  3. Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393:26–36. PubMed
  4. Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a dose-finding phase 2 trial. Lancet. 2021;398:2160–72. PubMed
  5. Garvey WT, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med. 2025;393:635–47. PubMed
Precision Equipment Protocol

Engineered for laboratory efficiency.

Metabolic research compounds are commonly handled in ready-to-use disposable pens or 3 ml cartridges compatible with standard reusable research pens — allowing exact, repeatable sequence handling.

🔬 CALCULATION TOOL

Research Calculator

For accurate sequence preparation across all metabolic research protocols.

Open Calculator →

Frequently Asked Questions

Common questions about these metabolic research compounds.

Which compound is right for my research?
Retatrutide is often preferred for broad metabolic effects targeting three receptors, whereas Tirzepatide is the industry leader for pure appetite suppression via dual GLP-1 and GIP pathways. Cagrilintide complements either as a satiety-focused amylin analogue.
How should compound quality be verified?
Confirm the identity and purity of every batch by HPLC and mass spectrometry before use, and check the certificate of analysis for that specific batch.
Can I use these compounds with my existing equipment?
Yes. Standard 3 ml cartridges are compatible with all standard reusable research pens, and pre-filled disposable pens are ready for immediate use. The Research Calculator converts concentrations into pen units.
Scroll to Top
Login / Register
BioCompounds UK Shield of Scientific Integrity

Welcome back